BridgeBio Pharma prices $150M public offering of common stock at $17.00/share

BridgeBio Pharma, Inc.

Offering of 8,823,530 shares (plus underwriters' 30-day option for 1,323,529 shares) at $17.00/share.
Gross proceeds ~$150M; net proceeds ~$143.1M after underwriting discounts and expenses.
Expected use of proceeds: fund clinical/pre-clinical development, research, working capital, and potential acquisitions.
Expected closing on or around March 10, 2023.
Goldman Sachs, Evercore, Morgan Stanley, and KKR Capital Markets are book-running managers.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

BridgeBio Pharma, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Morgan Stanley & Co. LLC valued at $17.00 per share (effective 2023-03-07).

Action: entry
Agreement: underwriting
Counterparty: Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Morgan Stanley & Co. LLC
Value: $17.00 per share
Effective: 2023-03-07

Exact text from the filing

On March 7, 2023, BridgeBio Pharma, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Morgan Stanley & Co. LLC, as representatives of the several underwriters listed on Schedule I thereto (collectively, the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 8,823,530 shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at a price to the public of $17.00 per share.

View on SEC.gov

84 material agreements filed in the last 30 days. Browse all material agreements →

BridgeBio Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-065459

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.